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Epstein-Barr virus (EBV) is associated with a wide
range of benign and malignant diseases, including
infectious mononucleosis, lymphoma, posttrans-
plant lymphoproliferative disorder, and nasopharyn-
geal carcinoma. Measurement of EBV viral load in
plasma is increasingly used for rapid assessment of
disease status. We evaluated the performance charac-
teristics of an EBV polymerase chain reaction assay
that uses commercial reagents and instruments from
Roche Diagnostics (Indianapolis, IN). DNA was ex-
tracted from plasma using a MagNaPure instrument,
and viral load was measured by real-time polymerase
chain reaction on a LightCycler. Analyte-specific re-
agents included primers and hybridization probes
targeting the EBV LMP2 gene and a spiked control
sequence. Accuracy and reproducibility were estab-
lished using DNA from three cell lines. The assay was
sensitive to approximately 750 copies of EBV DNA per
milliliter of plasma and was linear across at least four
orders of magnitude. The assay detected EBV DNA in
three of five samples from nasopharyngeal carcinoma
patients, seven of nine infectious mononucleosis sam-
ples, and 34/34 samples from immunosuppressed pa-
tients with clinically significant EBV-related disease,
whereas EBV DNA was undetectable in plasma from 21
individuals without EBV-related disease. In conclusion,
this LightCycler EBV assay is rapid, sensitive, and linear
for quantifying EBV viral load. The assay appears to be
useful for measuring clinically significant EBV levels in
immunodeficient patients. (J Mol Diagn 2006, 8:589–597;
DOI: 10.2353/jmoldx.2006.050152)
Viral load measurement is increasingly used in clinical
laboratories to assist in diagnosing and monitoring virus-
associated diseases. Primary Epstein-Barr virus (EBV)
infection is characterized by high plasma viral load that
declines to undetectable levels as the immune system
recognizes and controls the infection.1–3 Periodic reacti-
vation is accompanied by transient viremia and shedding
of virions in saliva.4 Some patients later develop EBV-
related neoplasms that are characterized by high circu-
lating levels of EBV DNA.5 Therefore, EBV viral load as-
says not only detect active infection but also serve as a
tumor marker for certain forms of malignancy.
Tumors that are almost universally EBV-associated in-
clude posttransplant lymphoproliferative disorder and
nasopharyngeal carcinoma, whereas cancers such as
acquired immune deficiency syndrome (AIDS)-related
lymphoma and Hodgkin lymphoma harbor EBV in only
about half of the cases.5 When a cancer is EBV-related,
the viral DNA appears to be present in virtually all of the
malignant cells, thus serving as a marker for the tumor
clone.6 However, the EBV genome is not restricted to
malignant cells as evidenced by high levels of EBV DNA
in whole blood and in fractions thereof.7 Circulating EBV
DNA levels are often elevated at the time of initial diag-
nosis and, in some cases, even before the cancer is
clinically evident.5,8–11 On effective treatment, EBV load
declines, suggesting that EBV DNA as a measure of
tumor burden is useful for monitoring efficacy of therapy
and early relapse.5,8,12,13
The advent of real-time polymerase chain reaction
(PCR) has greatly facilitated the quantitation of viral DNA
in human blood and tissue samples. Plasma is a conve-
nient sample type because EBV DNA levels are usually
very low or undetectable in plasma of healthy individuals,
whereas levels are elevated in conjunction with active
EBV infection and many EBV-related malignancies.5,14,15
The EBV found in plasma or serum usually exists in the
form of naked DNA rather than as encapsidated virions,
except in infectious mononucleosis where virions are also
commonly present.1,16 The cell-free DNA associated with
cancers is presumably derived from apoptosis or necro-
sis of infected malignant cells as suggested by strain
identity between plasma and tumor compartments.17–20
Well-designed real-time PCR assays are sensitive,
specific, reproducible, and linear across a wide dynamic
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range. In addition, because amplicons are sequestered
inside a closed vessel, the risk of amplicon contamination
is minimal. Accuracy, precision, and linearity of real-time
assays are theoretically better than with end-point prod-
uct quantitation methods. Technologist time is also lower
than with gel-based detection, even more so when ro-
botic systems are used to facilitate extraction. A variety of
real-time probe design strategies are feasible, including
TaqMan, molecular beacons, and fluorescence reso-
nance energy transfer.21–24 The combination of two prim-
ers and one or more internal probes, as well as the
potential for melt-temperature analysis of the probe bind-
ing region in certain assay designs, helps assure target
specificity. Finally, real-time PCR assays are more rapid
than gel-based PCR assays, thus allowing prompt inter-
pretation of test results.
In the current study, we implemented a commercial
real-time PCR assay for EBV DNA, and we evaluated its
performance characteristics. The assay relies on an au-
tomated extractor, a rapid thermocycler, and analyte-
specific reagents. A prior study by Ruiz et al evaluated a
kit version of this assay that is marketed by Roche Mo-
lecular Diagnostics in Europe,23 and another study by Le
et al demonstrated the clinical utility of the Roche EBV
PCR reagents in nasopharyngeal carcinoma patients.24
Our study is the first to use EBV genomic DNA prepared
from cell lines to evaluate assay sensitivity, accuracy,
reproducibility, and linearity. DNA from other herpesvi-
ruses was used to test specificity. Plasma samples from
patients with various EBV-related diseases and from con-
trols without EBV viremia were used to assess clinical
applicability.
Materials and Methods
EBV Viral Load Measurement
A commercial EBV viral load assay was validated using
three instruments from Roche Molecular Diagnostics (In-
dianapolis, IN), namely a Roche MagNaPure extractor, a
Roche LightCycler real-time thermocycler, and a Roche
LightCycler Carousel Centrifuge. Analyte specific re-
agents targeting the EBV latent membrane protein 2
(LMP2) gene and a spiked control sequence were also
from Roche Molecular Diagnostics. Sequences of prim-
ers and probes are proprietary. Detailed methods are
described to encourage standardized procedures that
permit results to be compared across laboratories.
The analyte-specific reagents are provided in separate
vials and include 1) Lightcycler EBV Primer/Hybridization
Probes, 2) Lightcycler EBV Recovery Template, which is
spiked into the sample before extraction, and 3) EBV
Template DNA, which represents a series of prediluted
standards by which to quantitate the virus. Reagents
were stored frozen at 15 to 25°C until use, at which
time the vials were thawed and gently flicked to dissolve
any precipitate and then stored refrigerated at 4°C pro-
tected from light for up to 1 month.
Blood anticoagulated with EDTA was centrifuged at
3000 rpm for 10 minutes, and plasma was removed to a
separate tube and frozen until analysis. A 200-l aliquot
of thawed plasma was spiked with 5 l of recovery tem-
plate (Roche Molecular Diagnostics), which is a synthetic
plasmid mimic sequence having the same primer binding
sites but a different internal probe recognition site from
the natural EBV LMP2 sequence. Total DNA was ex-
tracted on a MagNaPure instrument (Roche Molecular
Diagnostics) using the manufacturer’s external lysis pro-
tocol and extraction reagents (Total Nucleic Acid Isola-
tion Kit; Roche Molecular Diagnostics) to yield 100 l of
eluate. EBV LMP2 DNA was amplified in duplicate by
real-time PCR on the LightCycler (version 1.5). The
spiked control sequence was coamplified in the same
capillary. To test for false positive results due to reagent
contamination, each run contained a control in which no
template was added to the remaining reagents.
The LightCycler-FastStart DNA Master Hybridization
Probes (vial 1b) was centrifuged, and then 60 l of the
reaction mix was pipetted into vial 1a of FastStart enzyme
and mixed gently by pipetting up and down without vor-
texing. The mixture was relabeled using new labels pro-
vided by the manufacturer, one for the top of the cap and
one for the side of the vial, to indicate that the mixture is
a ready-to-use 10 “hot start” master mix. This reagent
was aliquoted and stored refrigerated at 2 to 8°C for a
maximum of 1 week. Each 20-l reaction contained 5 l
of template DNA, 2 l of 10 “hot start” master mix
(prepared from vials 1a and 1b), 2 l of Lightcycler EBV
Primer/Hybridization Probes, and 11 l of deionized dis-
tilled water (ddH2O).
The LightCycler was programed to automatically per-
form melt-curve analysis after amplification was com-
plete. The cycling parameters included an initial denatur-
ation step at 95°C for 10 minutes, followed by 45 cycles
at 95°C for 10 seconds, annealing at 55°C for 15 sec-
onds, and extension at 72°C for 15 seconds, with a
20°C/second transition time. The melt-curve parameters
were 95°C for 0 seconds, 40°C for 60 seconds with a
temperature transition rate of 20°C/second, and finally, a
slow rise in the temperature to 80°C at a rate of 0.1°C/
second with continuous acquisition of fluorescence data.
LightCycler software (version 3.5) was used to evaluate
amplification products in two fluorescence channels of
the LightCycler. EBV product was visualized in the F2/
back-F1 channel while the spiked control product was
visualized in the F3/back-F1 channel. Calibration of the
LightCycler must be done at least semiannually to dimin-
ish bleed through of fluorescence from one channel to
another.
The stock standards (EBV Template DNA; Roche Mo-
lecular Diagnostics) represent serial 10-fold concentra-
tions of 106 to 102 copies of EBV DNA per 5 l, and 5 l
of each standard DNA was added as template to each of
five reactions in every run. As the run progresses, Light-
cycler software automatically displays an amplification
curve in which accumulating fluorescence is visible. At
the conclusion of the run, the software produces a graph
of the standard curve of log concentration (x axis) versus
crossing point (y axis) across the five standards. In this
study, the slope of the standard curve was between
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3.14 and 3.64, spanning the ideal slope value of
3.33.
The viral load for each experimental sample was ex-
trapolated and automatically calculated by the LightCy-
cler software, in copies per reaction. The duplicate val-
ues were averaged and then manually multiplied by the
dilution factor of 100 to obtain an EBV viral load in copies
of EBV DNA per ml of plasma. For purposes of data
analysis, undetectable EBV DNA was reported as zero
copies.
The assay described above, which relies on analyte-
specific reagents from Roche, will heretofore be called
assay 1. For comparison purposes, EBV viral load was
also measured using assay 2 and assay 3, which are
both in-lab-developed real-time PCR assays in which
primers and a TaqMan probe target the BamH1W reiter-
ated EBV sequence in 96-well plates on an Applied Bio-
systems platform, namely the ABI Prism 7900 instrument
for assay 2 and the ABI Prism 7500 instrument for Assay
3 [Applied Biosystems, Inc. (ABI), Foster City, CA]. Re-
action content and cycling parameters are as previously
described,25 except that assay 2 used 10 l of template
DNA per 50 l PCR, whereas assay 3 used 5 l of
template DNA per 25 l of PCR and did not coamplify a
spiked control sequence. Assay 3 was performed on an
aliquot of the same MagNaPure-extracted eluate as as-
say 1, whereas assay 2 had to be performed on a sepa-
rate plasma aliquot that had been spiked with a different
control sequence (TaqMan Exogenous Internal Positive
Control DNA; Applied BioSystems) before MagNaPure
extraction to allow for multiplex amplification of the con-
trol sequence. Assay 2 and assay 3 both relied on stan-
dards prepared from the Namalwa Burkitt lymphoma cell
line.25 Both assay 2 and assay 3 were run in duplicate,
and viral load was calculated from the average copies
measured per PCR.
Assay Performance Characteristics
EBV DNA prepared from three different cell lines was
used to test assay sensitivity, accuracy, and linearity. The
Namalwa Burkitt lymphoma cell line DNA was 10-fold
serially diluted in ddH2O, representing 0.582 copies to
58,200 copies of EBV genome. B95.8 viral DNA (Ad-
vanced Biotechnologies, Inc., Columbia, MD) was 10-
fold serially diluted in ddH2O, representing 6.5 copies to
65,000 copies, and P3HR1 viral DNA (Advanced Biotech-
nologies, Inc.) was 10-fold serially diluted in ddH2O, rep-
resenting 7.5 copies to 75,000 copies of the EBV ge-
nome. In addition, to mimic actual patient samples,
Namalwa cell line DNA was spiked into EBV-negative
plasma at serial 10-fold dilutions such that, assuming
100% recovery of spiked EBV DNA after extraction, the
5-l template used in each PCR would represent input
levels of 0.582 to 58,200 EBV DNA copies per PCR. For
the Namalwa cell line DNA, EBV DNA concentration had
been determined by spectrophotometric measurement of
genomic DNA content in concert with prior research
showing two integrated copies of EBV genome per cell.26
For the B95.8 and P3HR1 products, both of which are
purified viral DNA, the manufacturer (Advanced Biotech-
nologies, Inc.) specified the concentration of EBV ge-
nome. Assay specificity was tested by analyzing other
herpes family viruses: cytomegalovirus, herpes simplex
virus, Kaposi’s sarcoma-associated herpesvirus, and
varicella-zoster virus. For each virus, 5 l of purified viral
DNA (Advanced Biotechnologies, Inc.) was used as PCR
template.
Clinical Samples
Residual plasma (n  69) was retrieved from the archives
of the University of North Carolina and affiliated hospitals.
A 200-l aliquot of this plasma had been previously as-
sayed for EBV viral load for purposes of patient care
using assay 2 on an ABI 7900 instrument, and residual
plasma was frozen at 20°C until the time it was thawed,
and a second 200-l aliquot was spiked and extracted
for analysis by both the LightCycler assay 1 and the ABI
7500 assay 3. Plasma samples were selected to repre-
sent a variety of benign and malignant disorders having
high, medium, low, or undetectable EBV loads by assay
2. Clinical information was obtained from medical
records. In addition, EDTA blood from healthy blood do-
nors was retrieved and centrifuged to prepare plasma.
This plasma was mixed with EBV-positive plasma to cre-
ate high volume plasma pools that were used to test
assay precision and reproducibility. This study was ap-
proved by our Institutional Review Board.
Results
The performance characteristics of assay 1 were exam-
ined using a series of DNA samples prepared from cell
lines. First, DNA from the Namalwa Burkitt lymphoma cell
line was serially diluted in water and used as template for
PCR to test assay sensitivity and linearity. Assay 1 was
sensitive to the lowest tested level (0.58 copies of EBV
DNA) and was linear over the entire 5-log range up to the
highest available level of 58,200 copies of template
(slope 1.2 versus ideal slope of 1.0, correlation coefficient
0.99 versus ideal of 1.0). We recognize that 0.58 copies
of EBV DNA is an absurd value, because the targeted
segment of the EBV genome was either present at one or
more copies per reaction or not present at all; see below
for further data and discussion on this point with regard to
accuracy and reproducibility.
When Namalwa DNA was spiked into plasma and
MagNaPure-extracted before being used as template,
remarkably, the assay was still sensitive to 0.58 copies of
template EBV DNA, although assay linearity was some-
what compromised (see Figure 1). On average, 79% of
EBV DNA was lost in the extraction process (range, 59 to
88%; see Table 1). For viral DNA prepared from the
P3HR1 Burkitt lymphoma cell line, the assay was sensi-
tive to 7.5 copies per PCR. The assay was not quite as
sensitive when tested on viral DNA prepared from the
B95.8 lymphoid cell line, detecting 65 but not 6.5 tem-
plate copies. It should be kept in mind that variation in
assay sensitivity across the various cell lines may reflect
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inaccuracies in the assigned concentration of EBV DNA
in each cell line sample.
Our assessment of accuracy varied by the source of
the EBV DNA (see Table 1). The results in the Namalwa
cell line, when used directly as template for PCR, were
remarkably accurate, with an average correlation of 93%
between the amount of EBV template put into the reaction
and the viral load measured by assay 1. For the P3HR1
cell line virus, there was a much greater difference be-
tween input and measured levels of EBV DNA, with the
proportion of measured to expected levels averaging 6%.
For the B95.8 cell line virus, there was also a substantial
difference, averaging 8% of expected levels. Despite the
magnitude of the differences, there was a fairly consistent
proportional difference across each dilution series of a
given stock DNA, suggesting that the “gold standard”
values for viral DNA concentration that had been as-
signed to each DNA stock were not always accurate. We
had no way of determining which stock had the most
accurate assigned EBV concentration.
The viral loads measured by assay 1 and assay 3 were
quite similar to each other, both in terms of absolute
copies detected per PCR and in terms of sensitivity to low
levels of input DNA (see Table 1). This correlation seems
remarkable given that different standards were used in
each of the two assays.
Specificity was tested by analyzing purified DNA from
four other herpesvirus family members. Assay 1 did not
cross-react with any of the other viruses tested including
cytomegalovirus, herpes simplex virus, Kaposi’s sarco-
ma-associated herpesvirus, and varicella-zoster virus.
Precision and Reproducibility
Intra-assay precision and interassay reproducibility were
assessed by first creating an EBV-positive plasma pool
and then making 1:10 and 1:100 dilutions in normal
plasma. Samples of the original pool and each dilution
were aliquoted into three vials each and extracted on the
MagNaPure for a total of nine extractions and then ana-
lyzed on the LightCycler in duplicate on 3 separate days
for a total of 54 PCR results. Extracted DNA was stored at
4°C before analysis. Intra-assay coefficient of variation
ranged from 4 to 8% in the pool with the highest EBV
load, 15 to 20% in middle pool, and 22 to 47% in lowest
pool, which contained EBV DNA at a level approaching
the lower limit of detection. EBV DNA was detectable in
all 18 replicates, even in the lowest pool. This result
implies that the analytic sensitivity of the LightCycler as-
say is no worse than the level present in the lowest pool
(12 copies per reaction, which is equivalent to 1200
copies per ml of plasma). Interassay coefficient of varia-
tion between run 1, run 2, and run 3 was 8, 20, and 40%
in the highest, middle, and lowest sample pools, respec-
tively (see Table 2).
Application to Human Plasma Specimens
A total of 69 human plasma samples were assayed by
LightCycler assay 1. Twenty-one of these plasma sam-
ples were from 21 patients or donors who were thought to
be free of EBV-related disease based on clinical findings
and on absence of viremia as shown by undetectable
EBV DNA by the ABI 7900 assay 2. The LightCycler
assay 1 revealed undetectable EBV DNA in all 21 sam-
ples. Thus, the two assays were in complete agreement
in all 21 specimens lacking evidence of EBV-related
disease.
Forty-eight residual plasma samples were evaluated
from 35 patients who were thought to have EBV-related
disease based on clinical findings and viremia as shown by
measurable EBV viral load by the ABI 7900 assay 2 (see
Table 3). When the LightCycler assay 1 was applied to
these plasma specimens, EBV DNA was detected in 42 of
48 samples. The remaining six specimens (two infectious
mononucleosis, two transplant, and two nasopharyngeal
carcinoma plasma samples) had undetectable EBV DNA
by assay 1 despite detectable EBV by assay 2 and assay 3,
albeit at a low level (range, 350 to 650 copies per ml of
plasma by assay 2, and 144 to 756 copies per ml of plasma
by assay 3). In nine specimens, only one of the two repli-
cates was positive by assay 1, again in conjunction with a
low viral load in the one positive test (range, 184 to 1101
copies/ml of plasma). In 33 samples with measurable viral
loads, the duplicate values by assay 1 were very close to
each other, never differing by more than twofold and aver-
aging a difference of 20%.
Results of the LightCycler assay 1 were evaluated in
comparison with results of the ABI assay 2 and the ABI
7500 assay 3 (see Figure 2). There was strong correlation
between the EBV viral loads measured by assay 1 com-
pared with assay 2 (correlation, 0.86) or assay 3 (corre-
Figure 1. EBV assay 1 performed on the Roche Lightcycler is sensitive,
accurate, and linear across a 5-log range. Genomic DNA from the Namalwa
Burkitt lymphoma cell line was used as template in PCR (A) or was spiked
into plasma and then extracted on the MagNaPure instrument before using as
template in PCR (B). The amount of input EBV DNA is shown on the x axis,
and the amount measured by the assay is shown on the y axis.
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lation, 0.85). Failure to detect EBV DNA in six specimens
implied that the Lightcycler assay 1 is slightly less sen-
sitive than the other assays when applied to patient
plasma samples.
To examine technical issues that could potentially con-
tribute to false negative EBV results by assay 1, we tested
for efficacy of extraction and for presence of amplification
inhibitors by first spiking a synthetic control sequence into
patient plasma before extraction. The spiked plasmid DNA
has been engineered to have the same primer recognition
sequences but a different internal probe sequence com-
pared with natural EBV LMP2. On subsequent real-time
Table 1. Assay Performance as Determined by Comparing Input Template Levels to Measured EBV Viral Load for Each of Four
Serially Diluted DNA Samples




Column 2 to column
1 ratio, %
ABI 7500 assay 3,
EBV viral load,
copies per PCR
Namalwa Burkitt Lymphoma Cell Line Genomic DNA
58,200 48,750 84% Not done*
5820 4896 84 Not done*
582 543 93 Not done*
58.2 41 70 Not done*
5.82 7 120 Not done*
0.58 0.6 103 Not done*
0 0 0
Purified P3HR1 EBV DNA
75,000 4424 6% 2299
7500 470 6 326
750 41 5 26
75 2.6 3 3
7.5 1.4 19 0.4
0.75 0 0
0 0 0
Purified B95.8 EBV DNA
65,000 5630 9% 3621
6500 573 9 565
650 61 9 60




Namalwa Burkitt cell line genomic DNA spiked into plasma
58,200† 12,930 22% 15,169
5820† 1003 17 1733
582† 65 11 210
58.2† 8 14 28
5.82† 2.4 41 6
0.58† 1 172 0.5
0 (plasma only) 0 0 Not done
*Serial dilutions of Namalwa DNA were used as the standard for assay 3, and therefore, it was inappropriate to use serial dilutions of Namalwa DNA
to test the performance characteristics of assay 3.
†For Namalwa DNA spiked into plasma and extracted before PCR, input EBV DNA levels are shown assuming that no EBV DNA was lost during
extraction.
Table 2. Intra-Assay Precision and Inter-Assay Reproducibility
Assay type Run no. Concentration
EBV viral load (copies/PCR)
Mean Range SD CV%
Intra-assay* Run 1 Original 881 761 to 944 70 8
10-fold dilution 107 75 to 124 19 18
100-fold dilution 12 8 to 23 5 47
Run 2 Original 771 722 to 802 29 4
10-fold dilution 83 60 to 106 16 20
100-fold dilution 9 5 to 12 3 31
Run 3 Original 834 782 to 888 46 6
10-fold dilution 103 83 to 126 15 15
100-fold dilution 16 12 to 21 4 22
Interassay† Run 1–3 Original 829 722 to 944 67 8
10-fold dilution 98 60 to 126 19 20
100-fold dilution 12 5 to 23 5 40
SD, standard deviation; CV, coefficient of variation.
*Means of six PCR replicates.
†Means of 18 PCR replicates.
Validation of LightCycler EBV PCR Assay 593
JMD November 2006, Vol. 8, No. 5
amplification of the spiked sequence, all of the patient sam-
ples had nearly identical amplification profiles, suggesting
that the extraction and amplification steps were quite con-
sistent and reproducible. Even when varying levels of EBV
DNA resulted in competition for reagents in this multiplex
PCR, the crossing points for the spiked control assay re-
mained around 32 to 33 cycles. Neither failed extraction nor
substantial inhibition of PCR occurred in this study.
Melt-curve analysis of the hybridization probe-binding
region showed that all but one of the EBV products had a
dissociation temperature of 61°C  2°C. The single outlier
had a dissociation temperature of only 54°C in both repli-
cates, suggesting the likelihood of a sequence variant in the
probe-binding region (see Figure 3). This sample was from
a patient with terminal multiorgan failure having an EBV viral
load of 13,545 copies per ml of plasma. Further testing was
not done to characterize the nature of the genetic defect
that altered the melt temperature. (The precise location of
probe hybridization in the LMP2 gene is proprietary infor-
mation not disclosed by the probe manufacturer.)
Discussion
This study represents the first comprehensive evaluation
of the performance characteristics of an assay that uses
commercial analyte-specific reagents for measuring EBV
viral load. The assay was optimized for implementation in
Table 3. EBV Load in 48 Plasma Samples from Patients with EBV-Related Disease
Case number Diagnosis







47 AIDS lymphoma 170,900 220,000 148,224
46 AIDS lymphoma 696,000 1029,200 513,897
48 AIDS lymphoma 369,750 1500,000 817,884
17 AIDS lymphoma 254 1280 2100
7 AIDS 92 1300 1409
20 AIDS 270 420 1096
31 AIDS 663 9000 12,554
33 AIDS 610 580 2573
21 Aplastic anemia 356 1400 1536
11 Autoimmune lymphoproliferative syndrome 127 630 1259
44 Terminal multi-organ failure after drug overdose 13,545 14,134 11,958
30 Infectious mononucleosis 570 1040 2067
1 Infectious mononucleosis 0 350 710
25 Infectious mononucleosis 455 3741 3242
26 Infectious mononucleosis 473 3140 4105
43 Infectious mononucleosis 2592 133,003 6232
41 Infectious mononucleosis 1844 912 812
42 Infectious mononucleosis 1416 399 1924
2 Infectious mononucleosis 0 351 177
37 Infectious mononucleosis 1261 654 484
27 Leukemia 476 11,500 10,286
45 Heart transplant 144,000 20,000 30,133
23 Heart transplant 411 2030 3822
3 Liver transplant 0 454 425
16 Liver transplant 253 1530 1230
28 Liver transplant 595 520 1684
9 Liver transplant 124 1200 985
14 Liver transplant 244 1400 1250
13 Liver transplant 211 990 850
34 Liver transplant 736 2018 1661
39 Liver transplant 1232 710 4106
24 Liver transplant 391 3170 619
36 Liver transplant 966 450 1042
29 Liver transplant 551 1265 1794
18 Liver transplant 266 819 1476
12 Liver transplant 151 413 423
8 Lung transplant 113 560 644
32 Lung transplant 711 2000 3934
15 Lung transplant 191 1500 3084
4 Lung transplant 0 400 380
10 Lung transplant 166 910 2793
35 Lung transplant 777 1770 1900
38 Marrow transplant 991 1143 1450
22 Nasopharyngeal carcinoma 401 311 652
40 Nasopharyngeal carcinoma 1752 2643 3455
5 Nasopharyngeal carcinoma 0 650 144
19 Nasopharyngeal carcinoma 388 3600 9288
6 Nasopharyngeal carcinoma 0 410 756
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our clinical laboratory where automated instruments and
software are used to facilitate extraction and detection of
amplification products. When the EBV-specific primers
and hybridization probes were applied to samples con-
taining known amounts of EBV DNA from any of three cell
lines, the assay was shown to be sensitive to approxi-
mately 7.5 copies of EBV per PCR reaction, which trans-
lates to 750 copies per ml of plasma. The assay was
linear across an average of four orders of magnitude,
although the linear range may have been underestimated
because the upper boundary was not studied. When
applied to residual plasma samples from patients with or
without viremia, the assay performed very well from a
clinical standpoint. All of the medically significant EBV
levels were identified in immunosuppressed individuals
where the LightCycler assay 1 was considered equiva-
lent to two other in-laboratory-developed assays.
A total of six samples had undetectable EBV by LightCy-
cler assay 1 in contrast to low EBV loads by the ABI 7900
assay 2 and by ABI 7500 assay 3 (up to 756 copies/ml),
implying that low-level EBV DNA was missed by the Roche
assay. False negative results were seen in two of nine
infectious mononucleosis patients, reinforcing prior studies
suggesting that serology rather than PCR be used as the
first line test to confirm a diagnosis of infectious mononu-
cleosis.1–3 Undetectable EBV results were seen in 2 of 22
transplant recipients; however, in both instances, the level
of EBV DNA by the other two assays was below our thresh-
old of 700 copies per milliliter of plasma, a threshold that
was validated to distinguish clinically significant EBV infec-
tion from the insignificant levels of plasma EBV that are
frequently found in healthy allogeneic transplant recipi-
ents.27 In nasopharyngeal carcinoma subjects, the Light-
Cycler assay 1 failed to detect low-level EBV DNA in two of
five plasma samples. Further studies of this patient group
are warranted to determine whether this difference is clini-
cally significant. Assay sensitivity may be critical in screen-
ing individuals at high risk for nasopharyngeal carcinoma,
especially those with early stage disease.12,17,24,28 In addi-
tion, carcinoma patients being followed for residual disease
after therapy may benefit from a sensitive assay to detect
early relapse.13,17,24
Contributing factors to assay sensitivity include 1) tar-
geting a single-copy gene versus a reiterated viral se-
quence, 2) signal-to-noise ratio in the detection system,
3) primer and probe design with associated optimization
of reaction components and cycling parameters, 4) mul-
tiplex versus single-target amplification, and 5) input
DNA volume. In the current study, the LightCycler assay
1 targeted the unique LMP2 gene, whereas the ABI as-
says 2 and 3 targeted the reiterated BamH1W sequence.
Assays 1 and 2 were both multiplexed with a spiked
control coamplification, whereas assays 1 and 3 both
used the same input DNA volume (5 l) versus 10 l for
assay 2. Despite all of these technical variables, the
assays performed remarkably similarly when applied to
either patient plasmas or to mock samples prepared from
cell lines.
False negative test results may also be a consequence
of failed extraction or PCR inhibition. Our study revealed
no evidence of either problem as shown by consistent
recovery of a spiked control sequence. Despite the
added expense of this control assay, we recommend its
use on a regular and ongoing basis to provide assurance
that extraction and amplification function as expected.
Another potential cause of false negative results is
sampling error, which is most evident clinically when
testing for low level disease or early relapse. In the cur-
rent study, duplicate testing sometimes revealed nega-
tive results in one of the replicates with a low viral load
measured in the other replicate, suggesting that sam-
pling error contributed to a false negative result in one of
the replicate wells. For purposes of patient care, one
should consider replicate analysis whenever clinical cir-
cumstances suggest that low positive versus negative
results would make a difference inpatient care. Further
studies are needed to determine whether replicate test-
ing would benefit nasopharyngeal carcinoma patients for
whom assay sensitivity seems to be important for screen-
ing high-risk individuals and for early detection of re-
lapse.13,28 On the other hand, replicate testing is proba-
Figure 2. EBV levels are shown as measured by three different viral load
assays in 48 plasma samples from patients with EBV-related disease. EBV
DNA was undetectable by LightCycler assay 1 in six patients who had
low-level EBV by the other two assays. In the remaining 42 samples, Light-
cycler assay 1 levels tended to be lower than those of the other two assays at
levels below 1000 copies per ml, whereas the values were quite similar across
the three assays for samples above 1000 copies per ml. It is not clear why the
values of all three assays correlated most closely at higher rather than lower
viral loads.
Figure 3. Melt-curve analysis reveals an abnormal melt temperature (Tm) in
duplicate EBV PCR assays on sample 44. This plasma sample was taken from
a woman with terminal multiorgan failure following a drug overdose. A
typical melt curve on the right has probe dissociation at approximately 61°C,
whereas the atypical melt curves on this particular sample have probe
dissociation at approximately 54°C.
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bly not required when monitoring allogeneic transplant
recipients because there is a low likelihood of missing a
clinically significant EBV-related posttransplant lympho-
proliferation as a consequence of sampling error. In this
regard, the Lightcycler assay is well suited for monitoring
transplant recipients.
Prior studies showed that most AIDS lymphoma pa-
tients whose tumors are EBV-related (as proven by in situ
hybridization) have moderate to high levels of circulating
EBV, but a few have low or undetectable levels in plasma,
and some with primary brain lymphoma had EBV DNA
detectable only in cerebrospinal fluid.14,29,30 In the cur-
rent study, we did not assess cerebrospinal fluid, but we
did show that the Lightcycler assay detected plasma EBV
DNA in all four samples from AIDS patients who had
EBV-related lymphoma.
Polymorphisms of EBV DNA can interfere with primer
or probe binding and thus alter viral load measurement.
Therefore, it is important to target highly conserved se-
quences within the viral genome. The LMP2 gene tar-
geted by LightCycler assay 1 is a highly conserved gene
that prevents antigen-mediated B lymphocyte activation,
thus promoting latent viral persistence by inhibiting the
cell from undergoing terminal differentiation. Our study
showed an abnormal melt curve in one patient sample,
which suggests there is a mutation in the EBV genome of
that patient’s strain of virus. The nature of the putative
polymorphism and its potential impact on viral pathoge-
nicity is beyond the scope of this study. In routine labo-
ratory practice, melt-curve analysis is an added benefit of
the hybridization probe format of the LightCycler assay 1
because it provides extra confidence in the specificity of
the assay.
A major advantage of a commercial assay is that all
testing laboratories have access to the same reagents
and equipment, thus facilitating standardization of testing
across many clinical laboratories. Standardization is es-
pecially important when patients are tested at more than
one laboratory, because serial monitoring of disease re-
quires use of equivalent tests to assure that trends are
interpreted correctly. Another advantage of standardiza-
tion is improved ability to compare proficiency survey
results across testing laboratories, whereas interlabora-
tory comparisons are difficult to interpret when each test-
ing laboratory uses different procedures, standards, and
units of reporting. Finally, commercial manufacturers of-
fer many different molecular products that complement
each other, thus facilitating use of their instruments and
reagents for many different applications merely by
switching out the analyte specific reagents. In this re-
gard, multiple patient samples may be extracted simul-
taneously and amplified simultaneously because the ex-
traction and cycling parameters are designed to be the
same for multiple different analytic tests. A downside of
commercial systems, beyond their expense, is that the
laboratory is at the mercy of the manufacturer to provide
a continuous pipeline of a high quality product. If the
manufacturer fails to deliver such product when needed,
the testing laboratory is faced with validating a back-up
assay or else sending samples to another laboratory that
may use a different test procedure, either of which can
confound interpretation of serial test results.
It was interesting to note that LightCycler assay 1
seemed to be as sensitive as assay 3 when tested on cell
line DNA, whereas it seemed to be less sensitive when
tested on actual patient samples. Even if true, this did not
appear to adversely impact the measurement of clinically
important levels of EBV in immunocompromised patients.
Furthermore, accuracy of assigned concentration values
is questionable in each of the three cell line DNA samples
that we tested. Two major factors are likely to contribute
to the variation in findings across the three cell lines. First,
Namalwa represents total DNA from an infected cell line,
so EBV DNA is mixed with abundant human DNA,
whereas the B95.8 and P3HR1 samples represent pure
viral DNA with little or no human DNA. The human DNA
may act as a blocker that nonspecifically binds to the
pipette tip and the reaction well, thus preventing viral
DNA from binding and thereby enhancing amplifiability of
viral sequences. Second, different methods were used to
determine the “correct” amount of EBV DNA in Namalwa
compared with the B95.8 and P3HR1 samples, with the
latter two samples coming from the same commercial
source and yielding results similar to each other. We
cannot determine which, if any, of the cell lines had the
more accurate assigned EBV concentration because
there is currently no “gold standard” by which to quanti-
tate EBV DNA. International effort is required to gain
agreement on a single, stable standard that can be used
by all testing laboratories to calibrate EBV viral load
assays.
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